Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today the publication of study results in the peer-reviewed journal Nature Communications.
The study demonstrates the power of the company’s platform to detect pancreatic cancer in its early stages, addressing the unmet need of more than 60,000 patients diagnosed with the disease each year in the United States alone. Read more . . .